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Available online xxxxChronic hepatitis leads to liver fibrosis and cirrhosis. Cirrhosis is a major cause of worldwidemorbidity andmor-
tality. Macrophages play a key role in fibrosis progression and reversal. However, the signals that determine
fibrogenic vs fibrolytic macrophage function remain ill defined. We studied the role of interleukin-4 receptor α
(IL-4Rα), a potential central switch of macrophage polarization, in liver fibrosis progression and reversal. We
demonstrate that inflammatory monocyte infiltration and liver fibrogenesis were suppressed in general IL-
4Rα−/− aswell as inmacrophage-specific IL-4Rα−/− (IL-4RαΔLysM)mice. However, with deletion of IL-4RαΔLysM
spontaneous fibrosis reversal was retarded. Results were replicated by pharmacological intervention using IL-
4Rα-specific antisense oligonucleotides. Retarded resolution was linked to the loss of M2-type resident macro-
phages, which secreted MMP-12 through IL-4 and IL-13-mediated phospho-STAT6 activation. We conclude
that IL-4Rα signaling regulates macrophage functional polarization in a context-dependent manner. Pharmaco-
logical targeting of macrophage polarization therefore requires disease stage-specific treatment strategies.
Research in Context: Alternative (M2-type) macrophage activation through IL-4Rα promotes liver inflammation
and fibrosis progression but speeds up fibrosis reversal. This demonstrates context dependent, opposing roles of
M2-type macrophages. During reversal IL-4Rα induces fibrolytic MMPs, especially MMP-12, through STAT6.
Liver-specific antisense oligonucleotides efficiently block IL-4Rα expression and attenuate fibrosis progression.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Chronic liver diseases can progress to cirrhosis, which is characterized
by excessive accumulation of scar tissue (extracellular matrix, ECM) that
is mainly composed of fibrillar collagens, glycoproteins and proteogly-
cans and that leads to severe distortion of the liver vascular architecture
(Schuppan and Afdhal, 2008). While activated myofibroblasts and he-
patic stellate cells (HSC) are the major producers of the fibrotic scar,
their fibrogenic activation and proliferation depends on a complex inter-
playwith other resident or recruited cells and their secreted factors. Here,
immune cells, which promote or attenuate fibrogenesis, have become
targets of antifibrotic treatments (Friedman et al., 2013; Schuppan and
Kim, 2013; Trautwein et al., 2015). Importantly, recent studies of highlythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2 S.-Y. Weng et al. / EBioMedicine xxx (2018) xxx–xxxeffective antiviral therapies in hepatitis B or C patients proved cirrhosis to
be a reversible condition, but the detailed mechanism underlying rever-
sal remain unclear (Chang et al., 2010; D'Ambrosio et al., 2012; Marcellin
et al., 2013).
As precursors of macrophages and dendritic cells, blood monocytes
are recruited to sites of injury by cytokines such as CCL2, CCL3 and
CCL6, which are abundant in patients with chronic liver diseases and cir-
rhosis (Karlmark et al., 2009; Marra et al., 1998; Shimizu et al., 2001). In
advanced CCl4-induced liver fibrosis, there is a massive recruitment of
CCL2/CCR2-guided monocytes that develop into CD11b+ F4/80+ Ly-6Chi
monocytic macrophages (Karlmark et al., 2009). These infiltrating cells
produce cytokines and chemokines with potent pro-inflammatory or di-
rect fibrogenic effects on HSC and (myo)fibroblasts, such as IL-1β, CCL2,
CCL5, CCL7, CCL8, CXCL4, TNFα, TGFβ-1, and PDGF-BB (Barron and
Wynn, 2011; Mehal and Schuppan, 2015; Ramachandran et al., 2012).
With cessation of the damaging stimulus and by yet ill-defined mecha-
nisms, these cells can undergo a shift towards an anti-inflammatory and
fibrolytic resident macrophage phenotype.
Resident macrophages may originate from Ly-6C− CCR2− mono-
cytes and have the potential to transform into classically (M1) or alter-
natively (M2) polarized macrophages in vivo (Egawa et al., 2013). M1-
andM2-type polarizations can be induced in vitro by cytokines that also
favor T helper (Th)1 vs Th2 cell polarization, i.e., by IFNγ and IL-12 vs IL-
4 and IL-13, respectively (Jaguin et al., 2013).M1-typemacrophages are
considered pro-inflammatory and potentially antifibrotic, while the role
of M2-type macrophages, which can be subdivided into at least 5 sub-
types, in inflammation and fibrosis is less well defined (Gundra et al.,
2017). The various M2-subtypes may exhibit either pro- or anti-fibrotic
activity (Borthwick et al., 2016; Gordon and Martinez, 2010; Murray et
al., 2014; Sica et al., 2014). This and other observations suggest that the
overall functional relevance of the classical M1 andM2 paradigm is lim-
ited (Murray et al., 2014). Therefore, also the utility of therapeutic ap-
proaches using classical Th1/M1 vs Th2/M2 polarizing cytokines
(Barron and Wynn, 2011; Duffield et al., 2013) remains unclear.
IL-4Rα that responds to both IL-4 and IL-13 should represent a cen-
tral switch for M1- towardsM2-typemacrophage polarization. Since its
cell specific function in inflammation and fibrosis has not been clearly
investigated, we extensively characterized its role during liver fibrosis
progression and regression, including its myeloid cell-specific deletion
and therapeutic inhibition.We show that macrophage IL-4Rα regulates
fibrosis progression and reversal discordantly through modulation of
macrophage subsets, indicating that antifibrotic therapies targeting IL-
4Rα require disease stage-specific pharmacological intervention.
2. Materials and Methods
2.1. Mice
Il4ra−/−, Il4/Il13 double knockout (DKO), Il4rafl/fl and LysMCre mice
were on a Balb/c background (Herbert et al., 2004; McKenzie et al.,
1999; Mohrs et al., 1999). Balb/c wild type mice were obtained from
Janvier (Saint Berthevin Cedex, France). For the generation of Il4raΔCD4
mice (CD4CreIl4raflox/flox) with T cell-specific deletion of IL-4Rα, CD4Cre
mice were mated with Il4raflox/flox mice. To generate Il4raΔLysM mice
(LysMCreIl4raflox/−) with myeloid-specific deletion of IL-4Rα, LysM-
CreIl4ra−/−, mice were bred with Il4raflox/flox mice. Littermates of LysM-
CreIl4raflox/− and Il4raflox/− were used as controls in all related studies.
All mice were housed under specific pathogen-free conditions. All ex-
periments were performedwith female 8- to 16-week-oldmice and ap-
proved by the ethical committee of the Government of Rhineland
Palatinate under the reference number 2317707/G12–1-007.
2.2. Fibrosis Models
Escalating CCl4 doses (0.875 mL/kg; week 1–3, 1.75mL/kg; week 4–
6, 2.5 mL/kg) were given via oral gavage three times per week during 6Please cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018weeks as described (Popov et al., 2011), to induce a primarily parenchy-
mal liver fibrosis. Fibrosis reversal was examined at 1, 2 or 4 weeks after
the last CCl4 treatment. For therapeutic intervention a 3 week CCl4-reg-
imen was chosen. Diet-induced liver fibrosis, resembling human nonal-
coholic steatohepatitis, was induced in 8-week old male mice that were
fed a methionine and choline deficient (MCD) diet for 8 weeks. Mice on
a methionine and choline sufficient diet (MCS) served as controls
(Wang et al., 2018).
2.3. In Vivo and In Vitro Application of Antisense Oligonucleotides (ASOs)
All 2nd-generation chimeric antisense nucleotides (ASOs)were pro-
duced by Ionis pharmaceuticals (Calsbad, CA) with base modifications
as described (Seth et al., 2008). To enhance binding affinity and avoid
degradation by nucleases, the phosphorothioate backbone nucleotides
were synthesized with 2-O-methoxyethyl (MOE) or locked 2-O, 4-C-
((S)-ethylidene) (cEt) modifications in the ribose backbone (3–5
bases at both ends), while the internal 10 nucleotides remained un-
changed. ASOswere administered 3 times per week (40 mg/kg in a vol-
ume of 10 μL PBS per g BW) by intraperitoneal injection. In short-term
progression experiments (CCl4 for 3 weeks) mice were treated with
ASOs during the 3 weeks. Alternatively, ASO treatment was started off
CCl4 for one week to assess efficacy during fibrosis regression. ASO se-
quences were as follows: Control ASO (Ionis 141923): 5′-
CCTTCCCTGAAGGTTCCTCC-3′; IL-4Rα ASO1 (Ionis 629123): 5′-AGTAG
GTAGGACAACA-3′; IL-4Rα ASO2 (Ionis 231894): 5′-CCGCTGTTC
TCAGGTGACAT-3′; STAT6 ASO: (Ionis 195428), 5′-CCACAGAGACATG
ATCTGGG-3′.
2.4. Hydroxyproline (Hyp) Determination
300mg liver tissue (150mg from the right and 150 mg from the left
liver lobe) was lysed in 5 mL HCl (6 N) at 110 °C for 16 h as previously
described(Popov et al., 2005). Briefly, the 5 μL of hydrogenated sedi-
ment and Hyp standards (5 points of serial dilutions) were incubated
with 50 μL citrate acetate buffer (5% citric acid, 7.24% sodium acetate,
3.4% NaOH and 1.2% glacial acetic acid, pH 6.0) and 100 μL of chlora-
mine-T solution (14.1 mg/mL chloramine T hydrate, 10% n-propanol,
80% citrate acetate buffer) for 30 min at room temperature. Then 100
μL of Ehrlich's reagent (0.17 g/mL 4-dimethylaminobenzaldehyde dis-
solved in 20.7% perchloric acid and 70.5% n-propanol) were added to
themixture and incubated at 65 °C for 30 min. The reactants weremea-
sured for absorbance at 550 nm. Hyp concentrations in liver tissuewere
determined by their absorbance relative to the standards after subtrac-
tion of the reaction after and before Ehrlich's reagent incubation.
2.5. Quantitative PCR
Liver samples (100 mg; 50 mg from the right and 50 mg from the
left liver lobe) were lysed in Trizol (Invitrogen, Carlsbad, CA) and 500
ng total RNA was used for reverse transcription (Quanta Bio, Gaithers-
burg, MD). cDNAs were subjected to qPCR using either the Taqman or
SYBR green technology (Applied Biosystems, Foster City, CA) and run
on a StepOnePlus real-time PCR system (Applied Biosystems, Foster
City, CA). Gene expression was normalized to expression of Gapdh.
Primers and probes are specified in the Supplemental Information.
2.6. Histology and Immunohistochemistry
Liver tissue was fixed in 4% Roth-Histofix (Carl Roth, Karlsruhe, Ger-
many), dehydrated, embedded in paraffin, sectioned and rehydrated as
described (Popov et al., 2005). For Sirius Red staining, rehydrated sec-
tions were exposed to 0.1% Direct Red (Sigma-Aldrich, St Louis, MO)
in saturated picric acid for 30 min. Slides were examined under the mi-
croscope using a 100× magnification and in each case 10 random fieldsroughMacrophagesDifferentially Regulates Liver Fibrosis Progression
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Health, Bethesda, MD).
For immunohistochemistry, rehydrated sections were boiled in 10
mM sodium citrate buffer for 10 min. Endogenous peroxidase was
quenched using 3% H2O2 in PBS and sections were blocked with 5%
goat or horse serum for 1 h, incubated for 1 h with the primary antibody
at 4 °C and finally exposed to either a biotinylated or a fluorochrome-
conjugated secondary antibody for 1 h at room temperature. The biotin
signal was amplified with the VECTASTAIN ABC kit (Vector Laboratories,
Burlingame, CA). Sections were developed with diamino-benzidine,
counterstained with Hematoxylin and mounted (Roti-Histokitt II, Carl
Roth, Karlsruhe, Germany). Fluorescent sections were treated with
DAPI (Sigma-Aldrich, St Louis, MO) and mounted using Fluoroshield
(Sigma-Aldrich, MO). Primary antibodies were directed to α-SMA
(Abcam, Cambridge, UK), Ym1 (Stemcell Technologies, Vancouver, Can-
ada), CD68 (Biorad, Hercules, CA), CD206 (Biolegend, SanDiego, CA) and
Ly-6G (BDBioscience, San Jose, CA). Secondary antibodieswere either bi-
otinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) or
Alexa Fluor 488 donkey anti-goat antibodies (Invitrogen, Carlsbad, CA).
2.7. Isolation of Hepatic Non-parenchymal Cells
Livers were minced and cells treated with collagenase buffer (0.4%
collagenase type IV, Sigma-Aldrich, St Louis, MO), 154 mM NaCl, 5.6
mM KCl, 5.5 mM glucose, 20.1 mM HEPES, 25 mM NaHCO3, 2 mM
CaCl2, 2 mMMgCl2, 1.6 nM DNase I (Applichem, Darmstadt, Germany)
(pH 7.4) and dispersed with a gentleMACS dissociator (Miltenyi Biotec,
Bergisch-Gladbach, Germany). Homogenates were incubated at 37 °C
for 30 min, passed through a 100 μm cell strainer (BD Bioscience, San
Jose, CA) and centrifuged at 21 ×g for 4 min in ice cold PEB buffer
(PBS, 2 mM EDTA, 0.5% BSA). Supernatants were centrifuged at 300 ×g
for 10 min and cell pellets were resuspended in PEB buffer. Red blood
cells were lysed by adding 10 volumes of 150 mM NH4Cl, 10 mM
KHCO3, 1 mM EDTA·2Na. Non-lysed immune cells were washed twice
and suspended in PEB buffer.
2.8. Isolation of Splenic CD4 T Cells
Spleens were harvested, passed through a 70 μm cell strainer (BD
Bioscience, San Jose, CA) and centrifuged at 300 ×g for 10 min in ice
cold PEB buffer. Pellets were resuspended in PEB and incubated with
CD4 microbeads at 4 °C for 15min. Labelled cells were washed, centri-
fuged, resuspended in PEB and separated using MACS columns
(Miltenyi Biotec, Bergisch-Gladbach, Germany).
2.9. Flow Cytometry
Non-parenchymal liver cellswere blockedwith the 2.4G2 anti-Fc re-
ceptor antibody (BD Bioscience, San Jose, CA) followed by staining with
antibodies recognizing CD4, CD8, CD11b, CD11c, CD19, CD45, CD86,
CD90.2, F4/80, IL-4Rα, Ly-6C, Ly-6G, MHCII (BD Bioscience, San Jose,
CA; Biolegend, San Diego, CA; eBioscience, San Diego, CA). For intracellu-
lar staining, cells were fixed in Fix/Perm buffer (BD Bioscience, San Jose,
CA), washed in PBS containing 2% serum and incubated in Perm/Wash
buffer (BD Bioscience, San Jose, CA) with an anti-CD206 antibody serving
as M2macrophage marker (eBioscience, San Diego, CA). For intracellular
detection of IL-4 and IL-13, cells were stimulated with phorbol
myristate acetate (PMA, 50 ng/mL), ionomycin (500 ng/mL) and
brefeldin (1 μg/mL) at 37 °C for 3 h, fixed, permeabilized as above and
subsequently stained with IL-4 and IL-13 antibodies (eBioscience, San
Diego, CA). For the determination of phospho-STAT6 or phospho-STAT3,
cells were either stimulated with IL-4 (20 ng/mL), IL-13 (20 ng/mL) or
IL-6 (100 ng/mL) at 37 °C for 30 min, fixed in 2% formaldehyde for 10
min and permeabilized with cold methanol. After permeabilization,
cells were stained with anti-phospho-STAT6 or -STAT3 (BD Bioscience,
San Jose, CA). Cell acquisition was performed on a FACS Canto II (BDPlease cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018Bioscience, San Jose, CA) and analyzed with the FLOWJO software
(TreeStar, Ashland, OR). Gating Strategy is demonstrated in Fig. S2. De-
tailed information on all antibodies is listed in Supplemental Information.
2.10. Cell Culture and Transfection
RAW264.7 murine macrophages (ATCC TIB-71) were seeded in 12-
well plates (105 per well). After 6 h, cells were transfected with IL-
4Rα-specific or control ASOs using the jetPEI-Macrophage DNA trans-
fection reagent (Polyplus, Illkirch, France). Sixteen hours after transfec-
tion, cells were harvested, lysed in Trizol (Invitrogen, Carlsbad, CA) and
subjected to qPCR analysis. For the isolation of peritoneal macrophages,
micewere euthanized and i.p. injectedwith 10mLDMEM/F12medium.
After a short soft massage of the abdominal area, a small incision was
made to recover the injectedmedium. Cells were isolated by centrifuga-
tion and plated in DMEMmedium (supplemented with 10% (v/v) fetal
bovine serum, 10 mM L-glutamine, 100 IU/mL penicillin, and 100 μg/
mL streptomycin). Nonadherent cells were removed 24 h later, and
cells were used for further experiments. For the isolation of bone mar-
row-derived macrophages, mice were euthanized, and femurs and tib-
ias removed. A small cut was made on both ends of the bones, and a
25-G needle attached to a syringe was inserted into the cavity to flush
out the bone marrow. The bone marrow cells were centrifugated and
then plated in differentiation RPMI-1640 medium (supplemented
with 10% (v/v) fetal bovine serum, 10mM L-glutamine, 100 IU/mL pen-
icillin, and 100 μg/mL streptomycin) containingM-CSF (25 ng/mL). Me-
dium was changed every 2–3 days, and cells were well differentiated
after oneweek. For in vitroM1polarization, cellswere treatedwith lipo-
polysaccharide (LPS, 1 μg/mL, Sigma-Aldrich, St Louis, MO) and IFN-γ
(20 ng/mL, BD Bioscience, San Jose, CA) for 24 h; for M2 polarization,
IL-4 (20 ng/mL, BD Bioscience, San Jose, CA) and IL-13 (20 ng/mL, BD
Bioscience, San Jose, CA) were applied for 24 h. Human monocytic
U937 cells were activated by PMA, 100 ng/mL for 48 h, to generate
nonpolarized (Mo) macrophages and left untreated or polarized to-
wards M1 using 100 ng/mL LPS and 20 ng/mL hIFNγ, or towards M2
using hIL-4 20 ng/mL and 20 ng/mL hIL-13 (PeproTech, Rocky Hill, NJ).
RNA was extracted, reverse transcribed and analyzed by qPCR.
2.11. Hydrodynamic Transfection
MMP-12 cDNA was cloned into the pcDNA3 vector to generate
pcDNA3-MMP12. The plasmids were purified using the QIAGEN Plas-
mid MAXI Kit (Qiagen, Hilden, Germany). Expression of MMP-12 was
assessed by SDS-PAGE and Western blotting (not shown). Mice were
treated for 6 weeks with CCl4. At day 3 after the last CCl4 injection
wildtype mice were i.v. injected once with plasmid DNA (pcDNA3
empty vector or pcDNA3-MMP12, 10μg/20 g body weight) mixed with
TransIT-QR Hydrodynamic Delivery Solution (Mirus, Madison, WI).
Groups of three mice were sacrificed and analyzed either 48 h or 11
days after hydrodynamic injection, for assessment of in vivo transfec-
tion efficacy and for fibrosis assessment, respectively. Proteins were ex-
tracted from 100 mg liver using RIPA buffer (Cell Signaling, Danvers,
MA) and cleared lysates resolved in a 4–10% polyacrylamide gel (Bis-
Tris, Thermo Fischer, Waltham, MA), transferred to a PVDF membrane
and detected with primary followed by secondary antibody (anti-
MMP-12 1:1000, anti-tubulin 1:5000, goat and mouse secondary anti-
body 1:5000, all Santa Cruz Biotechnology, CA) followed by the
Amersham ECL luminescence kit (GE, Chicago, IL).
2.12. Statistics
Data are shown as means ± SEM. Statistical differences were ana-
lyzed either with the 2-tailed unpaired Student's t-test (For comparison
between two groups) or one-way analysis of variance (one-way ANOVA
with Newman-Keuls' post-tests among multiple groups) using Graph
pad Prism 5.0 (GraphPad software, La Jolla, CA).roughMacrophagesDifferentially Regulates Liver Fibrosis Progression
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3.1. IL-4Rα Deficiency Retards Progression of Liver Fibrosis
Advanced liver fibrosis was induced in wildtype (WT) and IL-4Rα
deficient (Il4ra−/−) BALB/c mice by escalating doses of oral CCl4 for 6
weeks. Mice receiving vehicle served as controls (Fig. S1A). In WT ani-
mals hepatic Il4ra transcripts increased N2-fold during progression
(Fig. S1B). Morphometrical quantification of deposited collagen showed
that after 6 weeks of progression Il4ra−/−mice developed significantly
less fibrosis than their WT littermates (Fig. 1A). These results were con-
firmed by morphometrical quantification of alpha smooth muscle actin
(α-SMA), by biochemical collagen (hydroxyproline, HYP) quantifica-
tion and hepatic transcript levels of Col1a1 (Fig. 1B–C; Fig. S1C).
Serum ALT, a surrogate marker of liver inflammation, remained near
normal during progression in Il4ra−/−mice as compared to a 3-fold in-
crease in their WT controls (Fig. 1D). Collectively, these data provide in
vivo evidence for an active role of overall IL-4Rα signaling in promoting
liver inflammation and liver fibrogenesis during progression.
3.2. IL-4 and IL-13 Cytokines Are Important Drivers of Liver Fibrosis
Progression
Both IL-4 and IL-13 can activate IL-4Rα signaling. To investigate
whether loss of IL-4 and IL-13 will affect liver fibrosis progression, Il4/
Il13 double knockout (DKO) mice were subject to a 6-week course ofFig. 1. Loss of IL-4Rα signaling retards liver fibrosis progression. (A–D) Il4ra−/− and WTmice r
Sirius Red and (B) α-smooth muscle actin (α-SMA) staining of WT and Il4ra−/− liver sections;
fields of eachmouse (n= 6 per group). (C) Total liver collagen (hydroxyproline, Hyp). (D) Seru
with or without CCl4 treatment (n= 6 per group). (E-G) Il4/Il13 DKO and WT type mice receiv
staining (n = 5) of WT and Il4/Il13 DKO liver sections; bar: 200 μm. The diagrams depict m
mRNA (normalized to GapdhmRNA, n = 5). (G) Hepatic transcript levels of Mmp8, 12 and 1
(unpaired Student's t-test). All data are expressed as means± SEM. Results are representative
Please cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018CCl4 treatment. Histological analysis revealed reduced liver fibrosis in
the Il4/Il13 DKOmice as demonstrated by Sirius Red and α-SMA staining
(Fig. 1E; Fig. S1D), and by HYP determination (Fig. S1E). In line with this
finding, compared to their WT controls, CCl4-treated Il4/Il13 DKO mice
demonstrated a significant downregulation of serum ALT and of Col1a1,
matrix metalloproteinase (Mmp-8, -12 and -13) and tissue inhibitor of
MMPs (Timp-1) transcripts (Fig. S1F; Fig. 1F–G). In Il4ra−/−micenumbers
of IL-4- and IL-13-producing T cells were significantly reduced (Fig. S2A,
B), proving that constitutive IL-4Rα deficiency reduces absolute T cells.
3.3. IL-4Rα Loss of Function Changes Liver Macrophage Populations During
Liver Fibrosis Progression
InWTmice fibrosis induced by CCl4 lead to an increase of hepatic but
not splenic CD45+ immune cells in wildtype as well as Il4ra−/− mice
(Fig. 2A, B). However, differences between WT and Il4ra−/− immune
cells were found in the progression and early recovery phase of CCl4-in-
duced fibrosis, and evident in the hepatic B and CD4 T cell but not the
CD8 T cell population (Fig. 2C).
Since monocyte-macrophages have been implicated as important
regulatory cells in liver fibrosis progression and reversal, we focused
on the effect of IL-4Rα signaling in monocytic (CD11bhi F4/80int) and
resident (CD11bint F4/80hi) macrophages. FACS analysis demonstrated
that IL-4Rα deletion lead to a significant decrease of resident macro-
phages in the vehicle treated control group (Fig. 2D). Moreover, upon
CCl4 treatment the increase of pro-inflammatory Ly-6Chi monocyticeceived CCl4 or vehicle (mineral oil) for 6 weeks by oral gavage. (A–B) Representative (A)
bar: 200 μm. The diagrams depict mean percentages of stained areas from 10 microscopic
m alanine aminotransferase (ALT) levels inWT (white bars) and Il4ra−/− (black bars)mice
ed CCl4 or vehicle (mineral oil) for 6 weeks by oral gavage. (E) Representative Sirius Red
ean percentages of stained areas from 10 microscopic fields of each mouse. (F) Col1a1
3 and Timp1 in mice received vehicle or CCl4 (n = 5). *p b 0.05, **p b 0.01, ***p b 0.005
of two independent experiments.
roughMacrophagesDifferentially Regulates Liver Fibrosis Progression
.01.028
Fig. 2. IL-4Rα is required for infiltration bymonocyte-derived inflammatorymacrophages (Ly-6Chi CD11bhi F4/80int). Bar diagrams indicating absolute (A) splenic CD45+, and (B) hepatic
CD45+, (C) CD19+ (B cell), CD4 and CD8 T cell numbers of WT and Il4ra−/−mice that had received either mineral oil or CCl4 for 6 weeks. Analysis was performed one day, one and two
weeks after CCl4 withdrawal (n= 4 per group). (D) Representative FACS plots showing livermonocytes/macrophages (see also Fig. S2) ofWT and Il4ra−/−mice that were analyzed at the
end of 6 weeks of treatment with CCl4. In the two plots on the left resident macrophages (CD11bint F4/80hi) and monocytes/macrophages (CD11bhi F4/80lo) are shown. CD11bhi F4/80lo
cells were further subdivided into pro-inflammatory (Ly-6Chi) and anti-inflammatory (Ly-6Clo) monocytes/macrophages. Bar diagrams show the mean numbers of monocytes/
macrophages per liver (n = 4 per group). *p b 0.05, **p b 0.01, ***p b 0.005 (unpaired Student's t-test). All data are expressed as means ± SEM. Results are representative of ≥2
independent experiments.
5S.-Y. Weng et al. / EBioMedicine xxx (2018) xxx–xxxmacrophageswas significantly attenuated in livers of Il4ra−/−mice (Fig.
2D; Fig. S3A–G).
3.4. IL-4Rα Signaling Does Not Contribute to Fibrosis in a Model of Severe
Non-alcoholic Steatohepatitis
Severe hepatocyte lipoapoptosis was induced in mice receiving the
MCD diet for 8 weeks. Liver collagen was increased 4-fold in wild typePlease cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018mice, but fibrosis was not attenuated in Il4ra−/− mice, different from
mice with CCl4-induced liver fibrosis (Fig. S4A, B). Notably, there was
a downregulation of Il4ra in wildtype mice on the MCD vs the control
MCS diet, in contrast to micewith CCl4-induced liver fibrosis, and as ex-
pected its complete absence in the Il4ra−/−mice (Fig. S4C). Moreover,
IL-4Rα deletion did not affect macrophage CD68 expression, as in the
CCl4 as above model, indicating a less important role of this receptor
in fibrosis progression in this model (Fig. S4C).roughMacrophagesDifferentially Regulates Liver Fibrosis Progression
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We used optimized antisense oligonucleotides (ASOs) to the Il4ra
genewith high hepatic delivery (Kurreck et al., 2002; Lee et al., 2013)
that were first tested in vitro on RAW murine macrophages to dem-
onstrate a robust target knockdown compared to a negative control
ASO (Fig. S5A). For in vivo studies we chose ASO2 for its stronger in-
hibition of IL-4Rα expression (Fig. S5B). ASOs were applied during
CCl4-induced fibrogenesis for 3 weeks (Fig. 3A). During progression,
therapy with ASO2 strongly inhibited hepatic collagen deposition
(Fig. 3B) which was accompanied by a significant suppression of
Col1a1, α-SMA and Tgfb-1 transcripts (Fig. 3D). Moreover, ASO2 sig-
nificantly reduced the number of liver CD68+ macrophages and
levels of Cd68, iNOS and Mrc1 transcripts (Fig. 3C and E). TakenFig. 3. Inhibition of IL-4Rα expression by specific antisense oligonucleotides decreases fibrosis p
during three weeks of CCl4 treatment. (B) Sirius Red and (C) CD68 (macrophage) staining in
Relative hepatic transcript levels of key fibrosis-related genes in CCl4-treated mice receiving
macrophage marker genes (Cd68, Mrc1 and iNOS) for control oligonucleotide- and IL-4Rα
(unpaired Student's t-test). All data are expressed as means± SEM. Data are representative of
Please cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018together, IL-4Rα appears instrumental in increasing the influx of
monocyte-macrophages.
3.6. Loss of IL-4Rα Signaling in T Cells Does Not Alleviate Toxin-induced
Liver Fibrosis
IL-4Rα signaling and the associated Th2 T cell response are drivers of
portal liver fibrosis induced by Schistosomal parasites (Chiaramonte et
al., 1999; Pesce et al., 2009). To study the role of T cell IL-4Rα in our
model of parenchymal fibrosis progression and reversal, mice with a T
cell-specific IL-4Rα deletion (Il4raΔCD4) were generated and analyzed
in the progressionmodel. Quantitative PCR and flow cytometry demon-
strated a significant reduction of IL-4Rα in CD4+ T cells of Il4raΔCD4mice
(Fig. S6A–B), whereas several fibrosis related readouts showed norogression. (A)Mice received 9 doses of either control oligonucleotide (C) or IL-4Rα-ASO2
livers of mice with fibrosis progression. Bar: 200 and 50 μm, respectively (n= 4–5). (D)
either the control oligonucleotide or the IL-4Rα-specific ASO2. (E) Transcript levels for
-specific ASO2-treated livers during fibrosis progression (n = 5). *p b 0.05, **p b 0.01
three independent experiments.
roughMacrophagesDifferentially Regulates Liver Fibrosis Progression
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7S.-Y. Weng et al. / EBioMedicine xxx (2018) xxx–xxxdifference between control and Il4raΔCD4mice (Fig. S6C–E). Collectively,
this indicates that IL-4Rα signaling in T cells does not affect parenchy-
mal liver fibrosis progression or reversal.
3.7. Myeloid Cell-Specific Deletion of IL-4Rα Attenuates Fibrosis Progression
To address the role of macrophage IL-4Rα in liver fibrosis
progression, we generated mice with myeloid-specific IL-4Rα deletion
(Il4raΔLysM).When thesemice were subject to 6 weeks of CCl4, total he-
patic Il4ra expression was significantly suppressed compared to control
mice, with analysis shortly after the last dose of CCl4 (Fig. S6F).
Comparable to our findings in general Il4ra−/− mice, Sirius Red and
α-SMA staining, HYP content and Col1a1 expression showed attenuated
liver fibrogenesis and decreased ALT levels in Il4raΔLysM compared to
Il4rafl/− control mice (Fig. 4A–D). These results indicate that IL-4Rα
signaling throughmyeloid but no other hepatic cells plays an important
regulatory role in liver fibrosis progression.
3.8. IL-4Rα Is Specifically Deleted in Resident Macrophages in Il4raΔLysM
Mice during CCl4-induced Liver Fibrosis
A prior study showed that deletion of IL-4Rα in Il4raΔLysM in a Schis-
tosomiasis model was incomplete (Vannella et al., 2014). To unambigu-
ously define the cell type that drives IL-4Rα-mediated liver fibrogenesis
during progression, the number of myeloid lineage cells and their ex-
pression of IL-4Rα were investigated (Figs. S6G and S7A, B). We could
demonstrate that the abrogation of IL-4Rα, as mediated by LysM-Cre,
was highly efficient in resident macrophages (CD11bint F4/80hi), but in-
significant in neutrophils or Ly-6Chi or Ly-6Clo monocytic macrophages
(CD11bhi F4/80lo) (Fig. S7A, B). Refined FACS analysis showed a de-
creased expression of MHC class II and CD86 on these resident macro-
phages in Il4raΔLysM mice compared to control mice. This suggests that
the attenuated liver fibrosis in IL-4Rα deleted mice may be largely due
to fewer pro-inflammatory resident macrophages (Fig. S7C), but also
to fewer freshly recruited monocyte-macrophages which apparently
were only affected by the general IL-4Rα deletion (see Fig. 2D).
In linewith these findings, qPCR and immunohistochemical analysis
of livers of Il4raΔLysM mice, with a macrophage specific IL-4Rα deletion,Fig. 4.Myeloid IL-4Rα deficiency attenuates CCl4-induced liver fibrosis. Il4raf/− (control) andm
analyzed 3 days after the last dose of CCl4. (A) Representative Sirius Red (upper) and α-SMA (l
mean percentages of stained areas from 10microscopic fields per liver (n= 5). (B) Hepatic hyd
5). (D) Hepatic Col1a1 and α-SMA transcript levels (n= 5). Transcript levels were normalized
means± SEM. Results are representative of two independent experiments.
Please cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018showed a reduction of overall macrophages (CD68+), and of putative
M1-, but to a lesser degree also of M2-type populations, accompanied
by a decrease of Tgfb1 (profibrotic), iNOS and Il1b (M1), Arg1, Mrc1
and YM1 (M2) shortly after termination of 6 weeks of CCl4, when fea-
tures of both progression and early reversal may coexist (Fig. 5A–B).
We therefore conclude that liver fibrosis progression is mediated by
IL-4Rα partly through enhanced pro-inflammatory conversion of resi-
dent macrophages. There is also a reduction of M2-type macrophage
markers in Il4raΔLysM mice during progression and early reversal (3
days after cessation of CCl4) which likely impacts the fibrogenic over
the fibrolytic response.
3.9. Loss of IL-4Rα Reduces M2-type Macrophage Subsets and Retards
Spontaneous Liver Fibrosis Regression
To study the role of IL-4Rα in longer-term fibrosis reversal, we used
amodel of spontaneous fibrosis regression (6 weeks of CCl4 followed by
2 or 4 weeks without treatment), where fibrolytic macrophages play an
important role (Fig. S8A). As shown in Fig. S8B–D, approx. 30% of total
liver collagen deposition had disappeared after 2 weeks off CCl4 in WT
mice, whereas fibrosis resolution was retarded in Il4raΔLysM mice (Fig.
6A). This divergent effect during reversal vs progression was further
confirmed in a second experiment showing elevated Col1a1 and α–
SMA transcript levels in Il4raΔLysM vs the IL-4Rα expressing mice (Fig.
6B).
To confirm the translational relevance of these findings,we designed
a pharmacological intervention using a specific IL-4Rα ASO to fibrotic
WTmice during the reversal phase (Fig. 6C). Here, ASO2 significantly at-
tenuated resolution, as shown by a relative increase of liver collagen and
Col1a1mRNA expression vs mice treated with a scrambled control ASO
(Fig. 6D–E). Moreover, ASO2 significantly reduced the protein product
of the Mrc1 gene (CD206)+ M2-type macrophage numbers and sup-
pressed the M2-related genesMrc1 and Arg1, without affecting M1-re-
lated iNosmRNA (Fig. 6F–G) .
These results consistently showed that IL-4Rα regulates liverfibrosis
differently in fibrosis progression vs fibrosis reversal, and that this effect
is largely mediated by macrophages and no other IL-4Rα expressing
cells such as T cells or hepatocytes.yeloid cell IL-4Rα-deleted (Il4raΔLysM)micewere treatedwith CCl4 for 6 weeks. Micewere
ower) stained sections of CCl4 treated mice. Bar: 200 μm. The diagrams on the right depict
roxyproline (Hyp) levels (n= 5). (C) SerumALT levels of control and Il4raΔLysMmice (n=
to GapdhmRNA. *p b 0.05, **p b 0.01 (unpaired Student's t-test). All data are expressed as
roughMacrophagesDifferentially Regulates Liver Fibrosis Progression
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Fig. 5.Reduction of bothM1- andM2-typemacrophagemarkers in Il4raΔLysMmice during CCl4-induce liver fibrosis. (A) Transcript levels of Cd68, iNOS, Il1b, Tgfb1. Arg1 andMrc1 in control
and Il4raΔLysMmice treatedwithmineral oil or CCl4 for 6 weeks (n= 5). (B) Representative YM1 immunohistochemistry in control and Il4raΔLysMmice treatedwithmineral oil or CCl4 for
6 weeks (n= 5). Bar: 50 μm. *p b 0.05, **p b 0.01 (unpaired Student's t-test). All data are expressed as means± SEM.
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teinase Expression in Macrophages
MMPs are instrumental in ECM remodeling and fibrosis regression.
We therefore studied the expression of a panel of MMPs during early fi-
brosis reversal in control and Il4raΔLysM livers. In early reversal, at 24 or
72 h after CCl4 withdrawal, expression ofMmp12, 14, 16 and 20mRNA
was increased. At 72 hMmp16 and 20, and especiallyMmp12 transcripts
were significantly suppressed in Il4raΔLysM compared to control livers
(Fig. 7A and see also the Supplemental Information).
To study how far IL-4Rα signaling could directly potentiate the ex-
pression of Mmp12 in M2-type macrophages in vitro, peritoneal and
bone marrow-derived macrophages (BMDM) from WT and Il4ra−/−
mice were isolated and polarized with either IL-4 and/or IL-13 for 24 h.
M2 relatedMrc1 and Arg1 transcripts were up-regulated in WT but not
Il4ra−/−macrophages in response to IL-4 and IL-13 (Fig. S9A–B), suggest-
ing thatWT but not Il4ra−/−macrophages can be differentiated intoM2-
typemacrophages in vitro.Mmp12 transcriptswere prominently inducedPlease cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018in both primary WT but not Il4ra−/−macrophages after incubation with
IL-4 and/or IL-13 (Fig. 7B–C). Moreover, humanMMP-12 expressionwas
dramatically increased in PMA-activated U937 monocytes that were
treated with M2 (human IL-4 and IL-13) but not M1 cytokines (LPS and
human IFNγ) (Fig. S9C). Moreover, M1-polarized (LPS and IFNγ-treated)
WT and Il4ra−/− BMDMdid not show significant differences in their low
level ofMmp12 expression (Fig. S10A).
Phospho-STAT6 is a major downstream signal transducer for IL-
4/IL-13-dependent genes (Lin et al., 1995). In hepatic macrophages
lacking IL-4Rα, there was suppressed induction of phospho-STAT6
in response to IL-4 or IL-13 during fibrosis progression (Fig. 7D). In
this vein, ASOs targeting the IL-4Rα and STAT6 genes significantly
down-regulated Mmp12 mRNA in RAW macrophages (Fig. 7E). No
direct connection was found between M1 cytokines and MMP-12
expression and stimulation of macrophages with LPS did not en-
hance Mmp12 expression, neither in wildtype nor in IL-4Rα de-
leted cells (Fig. S10A). However, we found decreased pSTAT3-
activation in hepatic macrophages isolated from mice with CCl4roughMacrophagesDifferentially Regulates Liver Fibrosis Progression
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Fig. 6. IL-4Rα antisense oligonucleotides attenuate resolution and inhibit M2-type polarization during spontaneousfibrosis reversal. (A) Liver Hyp level of control and Il4raΔLysMmice after
2 weeks of CCl4 withdrawal (n= 5). (B) Transcript levels of Col1a1 and α-SMA of control and Il4raΔLysM mice after 2 weeks of CCl4 withdrawal (n= 6). (C–G) ASO2-mediated IL-4Rα
reduction caused the retardation of fibrosis reversal. (C) Mice received 3 doses of control oligonucleotide or ASO2 during the first week of reversal, off CCl4. Mice were analyzed one
day after the last dose of ASO2. (D) Representative Sirius Red staining in livers of mice during the reversal phase (n = 6). Bar: 200 μm. Bar diagrams represent results from 10
microscopic fields per liver. (E) Transcript levels for Col1a1. (F) Representative CD206 (M2-type macrophage) staining in livers of mice during the reversal phase (n= 6). Bar: 50 μm.
Bar diagrams represent results from 10 microscopic fields per liver. (G) Transcript levels for macrophage specific genes (Cd68, Mrc1, Arg1 and iNOS, n = 4). *p b 0.05 (unpaired
Student's t-test). All data are expressed as means± SEM. Results are representative of ≥2 independent experiments.
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(Fig. S10B).
To confirm that MMP-12 functions as an inducer of fibrolysis during
fibrosis reversal, an empty vector or a vector containingMmp12 cDNA
was delivered into fibrotic livers during the reversal phase using hydro-
dynamic transfection (Fig. S10C). Sirius Red staining showed that
Mmp12 cDNA but not the empty vector induced fibrosis resolution
(Fig. 7F). These results identify MMP-12 (and to a lesser degree MMP-
16 and -20) as primary bona fide mediator(s) of M2-type macro-
phage-mediated fibrolysis during the early phase of reversal.
In summary, inhibition of IL-4Rα expression ameliorated the pro-
gression but retarded regression of parenchymal liver fibrosis. There-
fore, targeting the IL-4Rα appears to be a therapeutic option for
patients with progressive liver fibrosis, but may retard resolution
when the inflammatory triggers are absent.
4. Discussion
IL-4 and IL-13 and their common receptor subunit IL-4Rα play a cen-
tral role inM2-typemacrophage and Th2 cell polarizationwhich are held
responsible for the promotion of organ fibrosis. Thus an IL-4 neutralizing
antibody or the dominant negative IL-13Rα1/2 antagonist sIL-13Rα2-Fc
reduced fibrosis in themousemodel of hepatic Schistosomiasis (CheeverPlease cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018et al., 1994; Chiaramonte et al., 1999). Here we demonstrate that, unex-
pectedly, IL-4Rα on macrophages promotes both hepatic inflammation
andfibrosis during progression,while it permits unrestrictedfibrosis res-
olution during spontaneous reversal. Notably,we showed that other cells
thanmacrophages (Bhattacharjee et al., 2013; Stein et al., 1992) or T cells
(Cheever et al., 1994; Chiaramonte et al., 1999) that can respond to IL-4
and IL-13, such as mast cells (Nilsson and Nilsson, 1995; Ochi et al.,
2000), eosinophils(Hao et al., 2000; Sher et al., 1990; Tomkinson et al.,
2001), (myo-)fibroblasts (Chandriani et al., 2014), and liver epithelial
cells (Richter et al., 2001), did not significantly contribute to liver inflam-
mation or fibrosis, which is strongly supported by our data demonstrat-
ing that the macrophage specific IL-4Rα-deletion (Il4raΔLysM) yielded
similar results as mice with the general IL-4Rα-knockout, with the
exception that it did not affect the freshly recruited monocyte-macro-
phages, as observed in mice with the general IL-4Rα. We also demon-
strate that, conversely, macrophage IL-4Rα signaling can also promote
liver fibrosis regression via STAT6-dependent transcriptional activation
ofMmp12, and that pharmacological inhibition of IL-4Rα recapitulated
the functional effects of genetic IL-4Rα deletion.
Schistosomiasis is associated with a prominent infiltration by Th2
cells. While these cells promote fibrogenesis, they also secrete IL-4
and IL-13 that was shown to induce an anti-inflammatory and
antifibrotic M2-type macrophage phenotype (Herbert et al., 2004;roughMacrophagesDifferentially Regulates Liver Fibrosis Progression
.01.028
Fig. 7. IL-4 and IL-13mediated STAT6 activation inducesmacrophageMMP-12 expression. (A) RelativeMmp transcripts (normalized toGapdh RNA) in livers of control and Il4raΔLysMmice
that were analyzed at 24 h and 72 h after 6 weeks of CCl4-treatment (n= 5). *p b 0.05, **p b 0.01; n, not significant (one-way ANOVA). (B,C) Peritoneal macrophages (pMφ) or bone
marrow-derived macrophages (BMDM) were either untreated or treated with IL-4 (20 ng/mL) and/or IL-13 (20 ng/mL) for 24 h.Mmp12 transcript were measured (n= 4 per group).
(D) Immune cells from Il4rafl/− control (C) and Il4raΔLysM (ΔLysM) livers were harvested at day three following CCl4 treatment and stimulated with IL-4 or IL-13 for 30 min for the
detection of phospho-STAT6 in macrophages (n = 4 per group). (E) Mmp12 transcript levels in RAW264.7 macrophages transfected with the indicated oligonucleotide. (F)
Representative Sirius Red staining of liver sections from mice three days after 6 weeks of fibrosis induction with CCl4 or from mice after 2 weeks of recovery after the last CCl4 dose.
Mice in the reversal group were injected with empty pcDNA3 vector (C) or pcDNA3-MMP12 (Mmp12). Bar diagrams show the quantification results. Bar: 200 μm. *p b 0.05, **p b 0.01,
***p b 0.005 (unpaired Student's t-test). All data are expressed as means ± SEM. See also the supplemental table of Mmp transcript levels.
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mice with chronic Schistosomiasis that showed increased liver inflam-
mation and fibrosis (Vannella et al., 2014). However, the role of these
cytokines and especially of IL-4Rα signaling in non-parasitic hepatic
liver disease, which is the prominent cause of liver fibrosis, had not
been addressed. While the innate immune response by monocytes/
macrophages and neutrophils usually precedes (T cell mediated) adap-
tive immunity (Campbell et al., 1981; Tacke and Zimmermann, 2014),
both the choice of the in vivo model and the timing of organ damage
or regeneration may determine how far Th2 cells or M2-type macro-
phages are primary drivers of inflammation or fibrosis. Th2 T cells are
important sources of IL-4, which together with IL-13 is the major ligand
for IL-4Rα. A recent paper indicated that IL-13 was produced by type 2
innate lymphoid cells (ILC-2) cells upon exposure to IL-33; however,
the deletion of ILC-2 under CCl4 treatment did not completely rule out
the participation of Th2 cells (McHedlidze et al., 2013). Thus we gener-
ated Il4raΔCD4 knockout mice to exclude a role of Th2 cells in the CCl4
model of parenchymal liver fibrosis, which had not been studied before.
In line with themajor finding of the paper byMcHedlidze, the Il4raΔCD4
knockout showed no difference compared to the wildtype control mice
under CCl4 treatment. Another recent study showed that IL-4 drives the
expression of surfactant protein SP-A in the lung and of complement
component C1q in the liver and peritoneal cavity, which amplify IL-
4Rα signaling in type-2 infectious models in these organs (Minutti et
al., 2017). It should be of interest to study how far C1q may also be in-
volved in our noninfectious liver fibrosis models. We have measuredPlease cite this article as:Weng, S.-Y., et al., IL-4 Receptor Alpha Signaling th
and Reversal, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018hepatic C1q transcripts at peak fibrosis and on days 1 and 3 of reversal.
Here we could not find significant differences between control and
Il4raΔLysM mice.
Our finding of a pro-inflammatory and pro-fibrogenic role of IL-4Rα
signaling during fibrosis progression, in contrast to its anti-inflamma-
tory and fibrolytic role during regression, relativates prior results with
IL-4, IL-13 or IL-13Rα2 in the models of pulmonary (Chandriani et al.,
2014), (Schistosomal) liver (Cheever et al., 1994; Chiaramonte et al.,
1999; Kaviratne et al., 2004) and intestinal fibrosis (Fichtner-Feigl et
al., 2007; Fichtner-Feigl et al., 2006), models that solely represent pro-
gression. These settings are also different from human (liver) fibrosis
which is characterized by foci or waves of progression and reversal,
even in advanced fibrosis (Wanless et al., 2000), features that can only
be represented by progression and reversal models as employed by us
(Issa et al., 2004; Popov et al., 2011). Finally, parenchymal rather than
portal liver fibrosis determines the degree of liver dysfunction and fail-
ure (Schuppan and Afdhal, 2008). Our data also suggest that IL-4Rα sig-
naling in macrophages may be an important regulator of inflammation
and fibrosis in the prevalent cases with parenchymal as opposed to por-
tal liver fibrosis.
Accordingly, therapeutic intervention targeting the IL-4Rα with a
specific antisense oligonucleotide that intrinsically addresses the liver
and preferentially macrophages (Butler et al., 2000) generated the
same effects as the macrophage specific (or constitutive) knockout of
IL-4Rα in the fibrosis models, as also shown by correlative comparison
of the change in fibrosis and the number and subtype of macrophagesroughMacrophagesDifferentially Regulates Liver Fibrosis Progression
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may suggest a prediction about the antifibrotic efficacy in patients
with liver fibrosis when either an IL-4Rα ASO or a dual human IL-4/IL-
13 blocking antibody, which has already entered the clinic and which
was developed for the treatment of asthma (Friedman et al., 2013;
Mehal and Schuppan, 2015; Schuppan and Kim, 2013), would be ap-
plied. Since therapeutic silencing of the IL-4Rα could be beneficial for
other inflammatory diseases such as ulcerative colitis, systemic sclerosis
and cancer, our findings may have broader translational implications.
Somewhat unexpectedly, ablation of IL-4Rα signalingduringfibrosis
progression not only reduced the number of hepatic M2-type macro-
phages, B and CD4+ T cells, but also increased pro-inflammatory (Ly-
6Chi CD11b+ F4/80int) macrophages. This indicates that IL-4Rα signal-
ing may increase not only monocyte recruitment but also potentiate
the transition from these proinflammatory monocytes to early forms
of monocytic macrophages. On the other hand, during reversal, IL-4Rα
deficiency reduced the number of the M2-type, potentially antifibrotic
(restorative) subset of Ly-6Clo CD11b+ F4/80int macrophages, likely in-
cluding resident macrophages, that may be mainly responsible for
fibrolytic remodeling (Madsen et al., 2013; Ramachandran et al.,
2012). Here we also show that fibrolysis was accompanied by STAT6-
dependent upregulation of macrophageMmp12 expression, an enzyme
which is specifically degrading elastin and collagens (Pellicoro et al.,
2012), major components of hepatic scar tissue.
Overall, blockade of IL-4Rα signaling has an anti-inflammatory
and anti-fibrotic effect during toxin-induced liver fibrosis progres-
sion and retards - but does not prevent - fibrosis resolution. Since
these context- and stage-specific in vivo effects of IL-4Rα signaling
in parenchymal liver fibrosis are mediated by macrophages and
closely linked to macrophage numbers and polarization, macro-
phage-targeted antifibrotic therapies will likely need to be adjusted
to the etiology and (inflammatory) activity of the underlying liver
disease.
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